A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors.

Citation

• Molife, L. R., Forster, M. D., Krebs, M., Pwint, T., Middleton, M. R., Kaye, S. B., . . . Ranson, M. (2010). A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors.. Journal of Clinical Oncology, 28(15_suppl), 2599. doi:10.1200/jco.2010.28.15_suppl.2599

Digital Object Identifier (doi)

• 10.1200/jco.2010.28.15_suppl.2599

Web Of Science Accession Number

Start Page

• 2599

End Page

• 2599

Volume

• 28

Issue

• 15_suppl

Abstract

UOW Authors

•   Ranson, Marie (external author)

Publication Date

• 2010

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Molife, L. R., Forster, M. D., Krebs, M., Pwint, T., Middleton, M. R., Kaye, S. B., . . . Ranson, M. (2010). A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors.. Journal of Clinical Oncology, 28(15_suppl), 2599. doi:10.1200/jco.2010.28.15_suppl.2599

Digital Object Identifier (doi)

• 10.1200/jco.2010.28.15_suppl.2599

Web Of Science Accession Number

Start Page

• 2599

End Page

• 2599

Volume

• 28

Issue

• 15_suppl